PLG and neoplasm: Urokinase-type plasminogen activator (PLAU1), which is overexpressed in different human cancer types (6–9), encodes a secreted serine protease that converts plasminogen to plasmin; this enzyme can promote tumor cell invasion and metastasis by degrading the components surrounding the extracellular matrix (10, 11).